Pages that link to "Q33927235"

The following pages link to Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment (Q33927235):

Displaying 46 items.

• Reduced serotonin reuptake transporter (SERT) function causes insulin resistance and hepatic steatosis independent of food intake (Q21134750) (← links)
• Fluoxetine versus other types of pharmacotherapy for depression (Q24245764) (← links)
• Ten putative contributors to the obesity epidemic (Q24619245) (← links)
• The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care (Q24682953) (← links)
• Treating Chronic Pain with SSRIs: What Do We Know? (Q26738470) (← links)
• Depression and the Link with Cardiovascular Disease (Q26752379) (← links)
• Paroxetine-The Antidepressant from Hell? Probably Not, But Caution Required (Q28069392) (← links)
• Effects of acute or repeated paroxetine and fluoxetine treatment on affective behavior in male and female adolescent rats (Q30373410) (← links)
• Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis. (Q33365152) (← links)
• A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? (Q33718185) (← links)
• Observational study of the impact of short-term duloxetine treatment on body weight in patients with major depressive disorder: a taiwanese perspective (Q33902245) (← links)
• Desvenlafaxine and weight change in major depressive disorder (Q33902252) (← links)
• Obesity and depression in adolescence and beyond: reciprocal risks. (Q33902519) (← links)
• Psychotropic medication use mediates the relationship between mood and anxiety disorders and obesity: findings from a nationally representative sample. (Q34049910) (← links)
• Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (Q34106516) (← links)
• Paroxetine: an update of its use in psychiatric disorders in adults (Q34118321) (← links)
• Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause (Q34243328) (← links)
• A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder (Q34264445) (← links)
• Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (Q34623350) (← links)
• Antidepressant use and diabetes mellitus risk: a meta-analysis (Q34886547) (← links)
• Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies (Q35574503) (← links)
• Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice (Q35996371) (← links)
• Comparing the effects of fluoxetine and imipramine on total cholesterol, triglyceride, and weight in patients with major depression (Q36565050) (← links)
• Premature ejaculation: definition and drug treatment (Q36757588) (← links)
• Relationship between SSRIs and Metabolic Syndrome Abnormalities in Patients with Generalized Anxiety Disorder: A Prospective Study (Q36941575) (← links)
• The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression (Q37187659) (← links)
• Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder (Q37397705) (← links)
• Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment. (Q37529769) (← links)
• Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey (Q37661052) (← links)
• The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. (Q37784203) (← links)
• A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder (Q38004948) (← links)
• Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity (Q38677949) (← links)
• Impact of concomitant medications on obstructive sleep apnoea. (Q38979483) (← links)
• Effect of sertraline on proliferation and neurogenic differentiation of human adipose-derived stem cells (Q39143491) (← links)
• Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic β cells (Q39218780) (← links)
• Paroxetine Can Enhance Neurogenesis during Neurogenic Differentiation of Human Adipose-derived Stem Cells (Q41992147) (← links)
• Serotonin Transporter Binding in the Diencephalon Is Reduced in Insulin-Resistant Obese Humans (Q42375205) (← links)
• Diet-induced changes in the Lean Brain: Hypercaloric high-fat-high-sugar snacking decreases serotonin transporters in the human hypothalamic region (Q42837765) (← links)
• The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials (Q43051350) (← links)
• The Trajectory from Mood to Obesity (Q47684242) (← links)
• Pharmacological Management of Anxiety Disorders in the Elderly (Q47758427) (← links)
• Differential SLC6A4 methylation: a predictive epigenetic marker of adiposity from birth to adulthood (Q61855017) (← links)
• Treating depression and anxiety in primary care (Q63979205) (← links)
• Managing depression in primary care: achieving remission (Q79968581) (← links)
• Preventive treatment of migraine: effect on weight (Q81973646) (← links)
• The effects of provider-prescribed obesogenic drugs on post-laparoscopic sleeve gastrectomy outcomes: a retrospective cohort study (Q91639736) (← links)